PROTAGONIST THERAPEUTICS INC's ticker is PTGX and the CUSIP is 74366E102. A total of 132 filers reported holding PROTAGONIST THERAPEUTICS INC in Q3 2022. The put-call ratio across all filers is 0.14 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $633,840 | -39.6% | 38,000 | 0.0% | 0.54% | -31.5% |
| Q2 2023 | $1,049,560 | +119987.0% | 38,000 | 0.0% | 0.79% | +15.1% |
| Q1 2023 | $874 | +110.6% | 38,000 | 0.0% | 0.68% | +133.4% |
| Q4 2022 | $415 | -99.9% | 38,000 | 0.0% | 0.29% | +30.2% |
| Q3 2022 | $320,000 | +6.3% | 38,000 | 0.0% | 0.22% | +2.7% |
| Q2 2022 | $301,000 | -66.6% | 38,000 | 0.0% | 0.22% | -66.2% |
| Q1 2022 | $900,000 | -30.8% | 38,000 | 0.0% | 0.65% | -22.7% |
| Q4 2021 | $1,300,000 | +93.2% | 38,000 | 0.0% | 0.84% | +83.0% |
| Q3 2021 | $673,000 | +49.9% | 38,000 | +280.0% | 0.46% | +70.3% |
| Q2 2021 | $449,000 | +73.4% | 10,000 | 0.0% | 0.27% | +74.7% |
| Q1 2021 | $259,000 | – | 10,000 | – | 0.15% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 2,449,183 | $19,373,000 | 4.95% |
| Bain Capital Life Sciences Investors, LLC | 2,260,572 | $17,881,000 | 2.10% |
| Finepoint Capital LP | 735,126 | $5,815,000 | 2.01% |
| Altium Capital Management LP | 365,100 | $2,888,000 | 1.16% |
| RTW INVESTMENTS, LP | 4,794,499 | $37,924,000 | 0.98% |
| Amitell Capital Pte Ltd | 50,129 | $397,000 | 0.90% |
| COWEN AND COMPANY, LLC | 1,065,724 | $8,430,000 | 0.81% |
| Tri Locum Partners LP | 155,000 | $1,226,000 | 0.50% |
| BVF INC/IL | 1,106,838 | $8,755,000 | 0.42% |
| HighVista Strategies LLC | 46,459 | $367,000 | 0.22% |